Clinical trials: Immune Checkpoint Inhibitor-Related Myocarditis, open to volunteers
Arrhythmia, Long QT Syndrome
AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis
ELDORA is a non-interventional observational data-science study aiming to develop and validate clinical-grade artificial intelligence tools applied to electrocardiogram (ECG) data.
- Conditions
- Arrhythmia, Long QT Syndrome, Immune Checkpoint Inhibitor-Related Myocarditis
- Trial name
- ELDORA (NCT07644715)
- Where
- France
- Volunteers
- 127,000 people, healthy volunteers welcome
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Myocarditis Acute, Cancer
Abatacept in Immune Checkpoint Inhibitor Myocarditis
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint…
- Trial name
- ATRIUM (NCT05335928)
- Testing
- Abatacept plus
- Where
- 31 sites in United States, Canada
- Volunteers
- 390 people
- Sponsor
- Massachusetts General Hospital
Cardiotoxicity, Cardiac Biomarkers
Cardiac Biomarkers in Patients Receiving Immune Checkpoint Inhibitors (PRIME-ICI)
Immune checkpoint inhibitors (ICIs) are widely used cancer treatments. Blood tests such as cardiac troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) can help clinicians investigate possible heart injury, but…
- Conditions
- Cardiotoxicity, Cardiac Biomarkers, Cancer
- Trial name
- PRIME-ICI (NCT07864727)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Immune Checkpoint Inhibitor-associated Myocarditis
ATROPOS: Survival Analysis of ICI-associated Myocarditis
ATROPOS is an international, registry-based observational study of cancer patients with immune checkpoint inhibitor-associated myocarditis (ICI-M).
- Trial name
- ATROPOS (NCT07633587)
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Immune Checkpoint Inhibitor-Related Myocarditis
Monitoring and Rehabilitation for ICIACI Rehabilitation：A Cohort Study
Immune checkpoint inhibitor-associated cardiac injury (ICIACI) is a low-incidence but highly fatal adverse event. A significant knowledge gap exists regarding the disease characteristics and recovery status of patients during the…
- Trial name
- NCT07278817
- Volunteers
- 340 people
- Sponsor
- China-Japan Friendship Hospital
Lung Cancer, Myocarditis Due to Drug
Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer
This study aims to investigate the clinical classification and outcome-related biomarkers of immune checkpoint inhibitor (ICI)-related myocarditis in patients with lung cancer.A total of 50 patients with ICI-related myocarditis…
- Trial name
- NCT06818149
- Testing
- Biomarker Analysis for Severity Assessment
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Breast Cancer, Hematologic Malignancy
Global Cardio Oncology Registry
G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and…
- Conditions
- Breast Cancer, Hematologic Malignancy, Immune Checkpoint Inhibitor-Related Myocarditis, Cardiotoxicity
- Trial name
- G-COR (NCT05598879)
- Testing
- anonymized data collection during programmed surveillance clinical follow up
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- The Cleveland Clinic
Immune Checkpoint Inhibitors Related Myocarditis
ICIAM Rehabilitation Program Study: A Randomized Controlled Trial
Immunotherapy has become a cornerstone in oncology; however, managing its associated adverse events poses a significant clinical challenge.
- Trial name
- NCT07280429
- Testing
- rehabilitation protocol
- Volunteers
- 60 people
- Sponsor
- China-Japan Friendship Hospital